- Subscribe to my blog via RSS
- Connect with me on LinkedIn
- Connect with me on Facebook
- Follow me on Twitter
Listen to internet radio with RemissionMan on Blog Talk Radio
Archives
- October 2022
- April 2022
- March 2022
- February 2022
- December 2021
- July 2021
- June 2021
- May 2021
- November 2020
- September 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- February 2016
- December 2015
- November 2015
- October 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- December 2008
- October 2008
- July 2008
- June 2008
- May 2008
- September 2007
- August 2007
- April 2007
- January 2007
Categories
Tags
50 fit tips bendeka be well philly big climb philly blood cancer brad schoener cancer cancer survivors chemotherapy chesapeakeman chronic lymphocytic leukemia cll crozer keystone cycling endurance sports expo ethan zohn ford ironman world championship grassroot soccer headstrong foundation ing nyc marathon ironman leukemia & lymphoma society liberty sports magazine Lls man of the year marathon motivation nyc marathon Philadelphia Insurance Triathlon philadelphia magazine philadelphia marathon philly health watch racing racing for reasons racing for recovery remission remissionman rituxan running survivor team in training training triathlon two oceans ultra marathon world triathlon corporation-
Recent Comments
- Robert A Mina on Cancer’s Give and Take
- M.L. Sicoli on Cancer’s Give and Take
- Joseph Romano on Cabrini University Healing Mass
- Jim Vail on Cabrini University Healing Mass
- Steve on Funk #9 & All Things Must Pass
FDA Approves Immunotherapy for Blood Cancer Patients
Today heralds a new era in cancer treatment with the U.S. Food and Drug Administration (FDA) approval of a new, cutting-edge gene therapy that reprograms a patient’s immune system to find and kill cancer cells. This highly personalized therapy known as Kymriah (previously CTL019 or tisagenlecleucel-T) signifies the promise of CAR (chimeric antigen receptor) T-cell immunotherapy, an approach that The Leukemia & Lymphoma Society (LLS) recognized early on held great promise for blood cancer patients.
In fact, LLS invested more than $20 million in research for this groundbreaking advance over the past two decades through multiple grants awarded to Carl June, M.D., and his team at the University of Pennsylvania and Children’s Hospital of Philadelphia, who pioneered this treatment. Novartis licensed the therapy from Penn in 2016.
LLS has also invested an additional $20 million to support CAR-T advances at other institutions, including Kite Pharma’s KTE-C19 (Axi-cel), also currently under review by the FDA for patients with lymphoma. LLS partnered with Kite Pharma to support its Phase 3 clinical trial since 2015 through its Therapy Acceleration Program® (TAP).
After receiving a unanimous recommendation from a review panel in July, the FDA approved Kymriah today for the treatment of pediatric and young adults 25 years of age and younger with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). More than 3,100 children and adolescents per year are diagnosed with ALL. The overall survival for ALL in children exceeds 85 percent, with these children undergoing between two and a half to three years of intense chemotherapy treatments. However, even patients who achieve an initial response to standard therapy will eventually relapse, and the prognosis is extremely poor for these patients. This CAR-T therapy is designed for those patients who have not responded to multiple previous treatments or are unable to remain in remission from their cancer.
“This is truly an exciting new day for cancer patients,” said Louis J. DeGennaro, Ph.D., LLS president and chief executive officer. “LLS recognized the promise of this innovative approach to treatment nearly 20 years ago. We first began to see remarkable outcomes for some of these patients in 2010 leading us to increase our funding of CAR-T therapy by supporting more than 10 major laboratories developing this method. We at LLS are extremely gratified to witness this lifesaving treatment approved so it is accessible to even more patients who desperately need new options.”
The FDA’s approval of Kymriah is based on positive data from a clinical trial showing that 83 percent of the patients treated achieved a complete response rate.
LLS is now funding the next generation of CAR-T therapy, where we anticipate the method will be useful in many different blood cancers, and perhaps even other major tumors that are difficult to treat such as brain, lung and colon cancer.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.
For additional information visit lls.org/lls-newsnetwork